Immunobiology

Publications

Alarcon, PC; Ulanowicz, CJ; Damen, MS M A; Eom, J; Sawada, K; Chung, H; Alahakoon, T; Oates, JR; Wayland, JL; Stankiewicz, TE; Moreno-Fernandez, ME; Zacharias, WJ; Salomonis, N; Divanovic, S. Obesity Uncovers the Presence of Inflammatory Lung Macrophage Subsets With an Adipose Tissue Transcriptomic Signature in Influenza Virus Infection. The Journal of Infectious Diseases. 2025; 231:e317-e327.

Allen, C; Chandrakasan, S; Jordan, MB; Leiding, JW; Marrone, M; Oladapo, A; Pednekar, P; Walkovich, K; Yee, J. Transplant Related Outcomes in Patients with Hemophagocytic Lymphohistiocytosis Treated with Emapalumab As a Bridge to Hematopoietic Stem Cell Transplantation (HSCT): The Real-HLH Study. Transplantation and Cellular Therapy. 2025; 31:s163-s164.

Brown-Burke, F; Saadey, R; Mao, HC; Marra, P; Brooks, E; Wandtke, A; Hout, I; Leon, S; Sharma, A; Yasin, A; Chen, C; Jordan, MB; Baiocchi, RA; Shindiapina, P. PRMT5 inhibition reduces hyperinflammation in a murine model of secondary hemophagocytic lymphohistiocytosis. Blood Advances. 2025; 9:2379-2392.

Chandrakasan, S; Allen, CE; Bhatla, D; Carter, J; Chien, M; Cooper, R; Draper, L; Eckstein, OS; Hanna, R; Hays, JA; Riskalla, M; Hobday, P; Baker, A; Ward, B. Emapalumab Treatment in Patients With Rheumatologic Disease-Associated Hemophagocytic Lymphohistiocytosis in the United States: A Retrospective Medical Chart Review Study. Arthritis and Rheumatology. 2025; 77:226-238.

Cook, E; Haacker, L; Chandra, S; Jordan, MB; Verkamp, B; McCarthy, L; Rotz, SJ; Hammoud, MS; Pariury, H; McKeone, D; Kumar, A. EBV-Associated T/NK-LPD Manifesting As HLH Cured By Nivolumab and Emapalumab, Avoiding the Need for Allogeneic HCT. Transplantation and Cellular Therapy. 2025; 31:s43.

Inamo, J; Keegan, J; Griffith, A; Ghosh, T; Horisberger, A; Howard, K; Pulford, JF; Murzin, E; Hancock, B; Dominguez, ST; Tuschl, T; Wofsy, D; Woodle, S; Wyse, A. Deep immunophenotyping reveals circulating activated lymphocytes in individuals at risk for rheumatoid arthritis. The Journal of Clinical Investigation. 2025; 135:e185217.

Jess, J; Verkamp, B; Jordan, M. Vitamin D Deficiency Is Prevalent and Resistant to Correction in Patients with Hemophagocytic Lymphohistiocytosis. 2025; 1.

Khoury, R; Jordan, M; Bleesing, J; Kumar, A; Saldana, BD; Verkamp, B; Davies, S; Marsh, R; Chandra, S. Addition of Thiotepa to Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Reduces Secondary Graft Failure in Allogeneic HSCT for Inborn Errors of Immunity. 2025; 1.

Marsh, R; Khoury, R; Mizuno, K; Hosawi, A; Cottrell, C; Nguyen, E; Landon, B; Chandra, S; Jordan, M; Kumar, A; Bleesing, J; Davies, S; Moore, C; Mehta, P. Precision Alemtuzumab Dosing Results in Day 0 Target Range Achievement in 80% of IEI Patients and Minimizes Risks of GVHD, Clinically Significant Mixed Chimerism, and Secondary Graft Failure. 2025; 1.

Steyn, S; Brown-Burke, F; Marra, P; Chen, C; Saadey, R; Mao, C; Weist, J; Klimaszewski, H; Hout, I; Leon, S; Vaddi, K; Jordan, MB; Baiocchi, R; Shindiapina, P. Exploring PRMT5 Inhibition As a Therapeutic Strategy in Primary and Secondary Hemophagocytic Lymphohistiocytosis. Transplantation and Cellular Therapy. 2025; 31:s159.

Warrick, KA; Vallez, CN; Meibers, HE; Pasare, C. Bidirectional Communication Between the Innate and Adaptive Immune Systems. Annual Review of Immunology. 2025; 43:489-514.

Wozny, N; Niebur, H; Jordan, M. T Cell Tropic Epstein Barr Virus in a Patient with Hemophagocytic Lymphohistiocytosis. 2025; 1.

Yarawsky, AE; Herr, AB. Assembly landscape of the complete B-repeat superdomain from Staphylococcus epidermidis strain 1457. Biophysical Journal. 2025; 124:363-378.

Zoref-Lorenz, A; Witzig, TE; Cerhan, JR; Jordan, MB. Malignancy-associated HLH: mechanisms, diagnosis, and treatment of a severe hyperinflammatory syndrome. Leukemia and Lymphoma. 2025; 66:628-636.